Advancements in the Treatment of Atherosclerosis: From Conventional Therapies to Cutting-Edge Innovations.

IF 4.9 Q1 CHEMISTRY, MEDICINAL

ACS Pharmacology and Translational Science Pub Date : 2024-12-04 eCollection Date: 2024-12-13 DOI:10.1021/acsptsci.4c00574

Yan Liu, Kuan Lu, Ruru Zhang, Dongliang Hu, Zhe Yang, Jianfeng Zeng, Wu Cai

{"title":"Advancements in the Treatment of Atherosclerosis: From Conventional Therapies to Cutting-Edge Innovations.","authors":"Yan Liu, Kuan Lu, Ruru Zhang, Dongliang Hu, Zhe Yang, Jianfeng Zeng, Wu Cai","doi":"10.1021/acsptsci.4c00574","DOIUrl":null,"url":null,"abstract":"<p><p>Atherosclerosis is a leading cause of morbidity and mortality worldwide, driven by a complex interplay of lipid dysregulation, inflammation, and vascular pathology. Despite advancements in understanding the multifactorial nature of atherosclerosis and improvements in clinical management, existing therapies often fall short in reversing the disease, focusing instead on symptom alleviation and risk reduction. This review highlights recent strides in identifying genetic markers, elucidating inflammatory pathways, and understanding environmental contributors to atherosclerosis. It also evaluates the efficacy and limitations of current pharmacological treatments, revascularization techniques, and the impact of these interventions on patient outcomes. Furthermore, we explore innovative therapeutic strategies, including the promising fields of nanomedicine, nucleic acid-based therapies, and immunomodulation, which offer potential for targeted and effective treatment modalities. However, integrating these advances into clinical practice is challenged by regulatory, economic, and logistical barriers. This review synthesizes the latest research and clinical advancements to provide a comprehensive roadmap for future therapeutic strategies and emphasize the critical need for innovative approaches to fundamentally change the course of atherosclerosis management.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 12","pages":"3804-3826"},"PeriodicalIF":4.9000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651175/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/acsptsci.4c00574","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/13 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Atherosclerosis is a leading cause of morbidity and mortality worldwide, driven by a complex interplay of lipid dysregulation, inflammation, and vascular pathology. Despite advancements in understanding the multifactorial nature of atherosclerosis and improvements in clinical management, existing therapies often fall short in reversing the disease, focusing instead on symptom alleviation and risk reduction. This review highlights recent strides in identifying genetic markers, elucidating inflammatory pathways, and understanding environmental contributors to atherosclerosis. It also evaluates the efficacy and limitations of current pharmacological treatments, revascularization techniques, and the impact of these interventions on patient outcomes. Furthermore, we explore innovative therapeutic strategies, including the promising fields of nanomedicine, nucleic acid-based therapies, and immunomodulation, which offer potential for targeted and effective treatment modalities. However, integrating these advances into clinical practice is challenged by regulatory, economic, and logistical barriers. This review synthesizes the latest research and clinical advancements to provide a comprehensive roadmap for future therapeutic strategies and emphasize the critical need for innovative approaches to fundamentally change the course of atherosclerosis management.

查看原文本刊更多论文

动脉粥样硬化治疗的进展：从传统疗法到前沿创新。

动脉粥样硬化是世界范围内发病率和死亡率的主要原因，由脂质失调、炎症和血管病理复杂的相互作用驱动。尽管在了解动脉粥样硬化的多因素性质和改善临床管理方面取得了进展，但现有的治疗方法往往无法逆转疾病，而是侧重于减轻症状和降低风险。这篇综述强调了最近在识别遗传标记、阐明炎症途径和了解动脉粥样硬化的环境因素方面取得的进展。它还评估了当前药物治疗、血运重建技术的有效性和局限性，以及这些干预措施对患者预后的影响。此外，我们还探索了创新的治疗策略，包括纳米医学、基于核酸的治疗和免疫调节等有前景的领域，这些领域为有针对性和有效的治疗方式提供了潜力。然而，将这些进步纳入临床实践受到监管、经济和后勤障碍的挑战。这篇综述综合了最新的研究和临床进展，为未来的治疗策略提供了一个全面的路线图，并强调了从根本上改变动脉粥样硬化治疗过程的创新方法的迫切需要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Pharmacology and Translational Science Medicine-Pharmacology (medical)

CiteScore

10.00

自引率

3.30%

发文量

133

期刊介绍： ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered. ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition. Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.